Chief Executive Officer
CurrentChannavix is developing a portfolio of non-opioid analgesics that are capable of providing multi-week pain relief with local administration. All of our programs have unique mechanisms of action without risk of addiction. These programs have successful proof-of-concept in animals with no observed toxicity and markedly reduced pain behavioral markers across inflammatory injection, incisional and induced arthritis models.